Company

MSICS PHARMA LTD

MSICS Pharma develops pharmaceutical products using naturally sourced psilocybin for mental health conditions.

About

Founded in 2020 by Roei Zerahia and Omer Zerahia, MSICS Pharma develops psilocybin-based treatments, including MSX-06, for conditions such as depression, OCD, anxiety and eating disorders. The company is based in Tel Aviv, Israel, and is conducting clinical trials with hospitals. In May 2026, it raised USD 3.6 million in venture funding led by Fusion, GlenRock Israel, SGL Acquisitions and Gooday Investment Ltd., with other investors also participating.

1Funding rounds

2Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in